DrugCard - Електронна система фармаконагляду

What

DrugCard is an electronic pharmacovigilance system focused on drug safety surveillance workflows. Based on the page content, it brings together local literature screening, global literature screening, regulatory intelligence, an adverse event database, automatic translation, and AI support tailored for drug safety.

The product appears designed for pharmacovigilance and drug safety teams that need to monitor medical literature, track health authority sources, and manage adverse event information more efficiently. Its likely positioning is a specialized safety operations platform that combines monitoring, search, translation, and database functions in one environment.

Features

• Local literature screening: Provides access to non-indexed journals, which can help safety teams identify relevant local case reports and publications that may not appear in mainstream databases.
• Global literature screening: Supports PubMed automation, reducing manual effort in ongoing international literature monitoring.
• Regulatory intelligence: Monitors health authority websites, which can help teams keep track of regulatory updates relevant to pharmacovigilance activities.
• Adverse event database: Offers an AI-powered database for adverse event handling, intended to support faster and more cost-efficient safety data work.
• Automatic translation: Helps users work with local-language sources, which is useful when screening international literature or regulatory content across markets.
• Advanced AI for drug safety: Includes AI functionality tailored to pharmacovigilance use cases, though the page does not specify the exact models or task-level capabilities.

Helpful Tips

• For products in this category, verify exactly how literature screening workflows are configured, including search logic, deduplication, triage, and auditability.
• If regulatory monitoring is important, confirm which health authority websites are covered and how alerts, change tracking, and review queues are handled.
• Automatic translation can improve reviewer speed, but regulated teams should assess when human verification is still needed for medical nuance and reportability decisions.
• Evaluate the adverse event database in terms of case intake structure, searchability, and how well it supports day-to-day pharmacovigilance operations; the source page does not provide detailed workflow evidence.
• Since AI is mentioned broadly, buyers should request clarity on where AI is applied in practice, such as classification, summarization, signal support, or literature review prioritization.

OpenClaw Skills

DrugCard could fit well into the OpenClaw ecosystem as the core safety intelligence layer inside broader pharmacovigilance workflows. Likely OpenClaw skills could include literature surveillance agents, health-authority monitoring agents, multilingual screening assistants, and adverse event triage workflows that collect findings from DrugCard and route them into review, escalation, or reporting processes. This is a likely use case rather than a confirmed native integration.

In practice, an OpenClaw-based setup around DrugCard could help pharmacovigilance teams automate repetitive monitoring and first-pass analysis while preserving human review for medical judgment. For pharmaceutical safety operations, that combination could shift work from manual search and translation toward exception handling, signal assessment, and faster cross-market coordination.